Combining Good Practices : Method to study Introductory Physics in Engineering Education

Julkaisumaa: 056 BE BEL Belgia

Eficácia do herbicida amicarbazone aplicado sobre a palha ou no solo no controle de plantas daninhas na cultura da cana-de-açúcar

A eficácia dos herbicidas no sistema de cana-crua é diretamente influenciada pela quantidade e distribuição de palha na área, bem como pela ocorrência da primeira chuva superior a 20 mm posterior à aplicação, uma vez que a palha é capaz de interceptar o herbicida antes que este atinja o solo. Nesse contexto, a presente pesquisa teve como objetivo avaliar a eficácia e o comportamento do herbicida amicarbazone no controle de plantas daninhas no sistema de cana-crua. Para isso, foi realizado um experimento em condições controladas, considerando diferentes doses de amicarbazone (D1 = 1,05 kg ha-1, D2 = 0,875 kg ha-1, D3 = 0,700 kg ha-1 e D4 = 0,525 kg ha-1) e situações de aplicação desse herbicida, a saber: sobre 5 t de palha ha-1, sobre o solo e coberto com 5 t de palha ha-1, além de pulverização sobre o solo sem cobertura de palha, resultando assim em 12 tratamentos. Aos 7, 14, 21 e 28 dias após a aplicação (DAA), foi avaliada a porcentagem de controle das seguintes espécies de plantas daninhas: Ipomoea grandifolia, Brachiaria decumbens, Merremia cissoides e Euphorbia heterophylla. Pelos resultados obtidos, pode-se constatar que, independentemente da espécie de planta daninha avaliada, os maiores índices de controle foram observados quando o amicarbazone foi aplicado sobre a palha, simulando-se em seguida precipitação correspondente a 30 mm de chuva, e nos tratamentos em que o herbicida foi aplicado diretamente no solo sem palha. Dessa forma, para as espécies I. grandifolia, M. cissoides e E. heterophylla, todos os tratamentos apresentaram excelente controle (nota 6 - 100%) a partir dos 14 DAA; para B. decumbens, o controle total ocorreu aos 28 DAA. Portanto, pode-se concluir que o amicarbazone é uma excelente alternativa para o manejo dessas espécies de plantas daninhas em cana-crua.

Interferência das plantas daninhas sobre a produtividade e qualidade de cenoura

Com o objetivo de avaliar a interferência das plantas daninhas sobre a produtividade e qualidade de cenoura (Daucus carota), foi realizado um experimento no período de julho a outubro de 2007, em Mossoró-RN. O delineamento experimental utilizado foi o de blocos casualizados, com seis tratamentos e quatro repetições. Os tratamentos consistiram de seis períodos de controle de plantas daninhas, em que a cultura da cenoura permaneceu livre da competição com essas plantas, por meio de capinas, a partir da emergência: 0-12, 0-24, 0-36, 0-48, 0-60 e 0-72 dias (testemunha mantida no limpo). As características avaliadas foram: produtividade comercial de raízes, teores de sólidos solúveis (SS), acidez total (AT), vitamina C e pH de raízes. A produtividade comercial de raízes de cenoura foi alterada pela convivência da cultura com as plantas daninhas, a qual respondeu a capinas até os 40 e 37 DAE, tolerando-se perdas de produtividade de 5 e 10%, respectivamente, em relação ao tratamento mantido no limpo durante todo o ciclo. Os teores de SS e de vitamina C não foram influenciados pela interferência das plantas daninhas, ao passo que a maior convivência da cultura com as plantas daninhas resultou em acidez total e pH das raízes mais elevados e menor relação sólidos solúveis/acidez total.

Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives

Dopamine constitutes about 80% of the content of central catecholamines and has a crucial role in the etiology of several neuropsychiatric disorders, including Parkinson's disease, depression and schizophrenia. Several dopaminergic drugs are used to treat these pathologies, but many problems are attributed to these therapies. Within this context, the search for new more efficient dopaminergic agents with less adverse effects represents a vast research field. The aim of the present study was to report the structural design of two N-phenylpiperazine derivatives, compound 4: 1-[1-(4-chlorophenyl)-1H-4-pyrazolylmethyl]-4-phenylhexahydropyrazine and compound 5: 1-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-ylmethyl]-4-phenylhexahydropyrazine, planned to be dopamine ligands, and their dopaminergic action profile. The two compounds were assayed (dose range of 15-40 mg/kg) in three experimental models: 1) blockade of amphetamine (30 mg/kg, ip)-induced stereotypy in rats; 2) the catalepsy test in mice, and 3) apomorphine (1 mg/kg, ip)-induced hypothermia in mice. Both derivatives induced cataleptic behavior (40 mg/kg, ip) and a hypothermic response (30 mg/kg, ip) which was not prevented by haloperidol (0.5 mg/kg, ip). Compound 5 (30 mg/kg, ip) also presented a synergistic hypothermic effect with apomorphine (1 mg/kg, ip). Only compound 4 (30 mg/kg, ip) significantly blocked the amphetamine-induced stereotypy in rats. The N-phenylpiperazine derivatives 4 and 5 seem to have a peculiar profile of action on dopaminergic functions. On the basis of the results of catalepsy and amphetamine-induced stereotypy, the compounds demonstrated an inhibitory effect on dopaminergic behaviors. However, their hypothermic effect is compatible with the stimulation of dopaminergic function which seems not to be mediated by D2/D3 receptors.

Presence of autoantibodies against HeLa small nuclear ribonucleoproteins in chagasic and non-chagasic cardiac patients

We detected anti-human small nuclear ribonucleoprotein (snRNP) autoantibodies in chagasic patients by different immunological methods using HeLa snRNPs. ELISA with Trypanosoma cruzi total lysate antigen or HeLa human U small nuclear ribonucleoproteins (UsnRNPs) followed by incubation with sera from chronic chagasic and non-chagasic cardiac patients was used to screen and compare serum reactivity. Western blot analysis using a T. cruzi total cell extract was also performed in order to select some sera for Western blot and immunoprecipitation assays with HeLa nuclear extract. ELISA showed that 73 and 95% of chronic chagasic sera reacted with HeLa UsnRNPs and T. cruzi antigens, respectively. The Western blot assay demonstrated that non-chagasic cardiac sera reacted with high molecular weight proteins present in T. cruzi total extract, probably explaining the 31% reactivity found by ELISA. However, these sera reacted weakly with HeLa UsnRNPs, in contrast to the chagasic sera, which showed autoantibodies with human Sm (from Stefanie Smith, the first patient in whom this activity was identified) proteins (B/B', D1, D2, D3, E, F, and G UsnRNP). Immunoprecipitation reactions using HeLa nuclear extracts confirmed the reactivity of chagasic sera and human UsnRNA/RNPs, while the other sera reacted weakly only with U1snRNP. These findings agree with previously reported data, thus supporting the idea of the presence of autoimmune antibodies in chagasic patients. Interestingly, non-chagasic cardiac sera also showed reactivity with T. cruzi antigen and HeLa UsnRNPs, which suggests that individuals with heart disease of unknown etiology may develop autoimmune antibodies at any time. The detection of UsnRNP autoantibodies in chagasic patients might contribute to our understanding of how they develop upon initial T. cruzi infection.

RANK, RANKL and osteoprotegerin in arthritic bone loss

Rheumatoid arthritis is characterized by the presence of inflammatory synovitis and destruction of joint cartilage and bone. Tissue proteinases released by synovia, chondrocytes and pannus can cause cartilage destruction and cytokine-activated osteoclasts have been implicated in bone erosions. Rheumatoid arthritis synovial tissues produce a variety of cytokines and growth factors that induce monocyte differentiation to osteoclasts and their proliferation, activation and longer survival in tissues. More recently, a major role in bone erosion has been attributed to the receptor activator of nuclear factor kappa B ligand (RANKL) released by activated lymphocytes and osteoblasts. In fact, osteoclasts are markedly activated after RANKL binding to the cognate RANK expressed on the surface of these cells. RANKL expression can be upregulated by bone-resorbing factors such as glucocorticoids, vitamin D3, interleukin 1 (IL-1), IL-6, IL-11, IL-17, tumor necrosis factor-alpha, prostaglandin E2, or parathyroid hormone-related peptide. Supporting this idea, inhibition of RANKL by osteoprotegerin, a natural soluble RANKL receptor, prevents bone loss in experimental models. Tumor growth factor-ß released from bone during active bone resorption has been suggested as one feedback mechanism for upregulating osteoprotegerin and estrogen can increase its production on osteoblasts. Modulation of these systems provides the opportunity to inhibit bone loss and deformity in chronic arthritis.

HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors

Anti-HBc positivity is a frequent cause of donation rejection at blood banks. Hepatitis B virus (HBV) infection may also occur in HBsAg-negative patients, a situation denoted occult infection. Similarly, very low levels of HBV-DNA have also been found in the sera of patients with chronic hepatitis C virus (HCV) infection, even in the absence of serum HBsAg. Initially we searched for HBV-DNA in serum of 100 blood donors and 50 HCV-infected patients who were HBsAg negative/anti-HBc positive by nested-PCR and by an HBV monitor commercial test for HBV-DNA. Anti-HBs seroconversion rates were measured in 100 blood donors and in 22 patients with chronic HCV infection after HBV vaccination to determine if the HBV vaccination could eliminate an occult HBV infection in these individuals. Occult HBV infection was detected in proportionally fewer blood donors (6/100 = 6%) than chronic hepatitis C patients (12/50 = 24%) (P < 0.05). We noted seroconversion in 6/6 (100%) HBV-DNA(+) and in 84/94 (89.4%) HBV-DNA(-) blood donors (P > 0.05). All subjects who were HBV-DNA(+) before the first dose of HBV vaccine (D1), became HBV-DNA(-) after D1, D2, and D3. Among 22 HCV-positive patients, 10 HBV-DNA(+) and 12 HBV-DNA(-), seroconversion was observed in 9/10 (90%) HBV-DNA(+) and in 9/12 (75%) HBV-DNA(-) subjects (P > 0.05). The disappearance of HBV-DNA in the majority of vaccinated patients suggests that residual HBV can be eliminated in patients with occult infection.

De arbitris pacis

Invokaatio: Altissimo propitio!